Studie - Hypercalcemia – Pipeline Review, H1 2012

Hypercalcemia — Pipeline Review, H1 2012


Summary


Global Markets Direct’s, 'Hypercalcemia - Pipeline Review, H1 2012', provides an overview of the Hypercalcemia therapeutic pipeline. This report provides information on the therapeutic development for Hypercalcemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hypercalcemia. 'Hypercalcemia - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


Scope

- A snapshot of the global therapeutic scenario for Hypercalcemia.
- A review of the Hypercalcemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Hypercalcemia pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.


Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Hypercalcemia.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Hypercalcemia pipeline depth and focus of Hypercalcemia therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table of Contents

Table of Contents 2

List of Tables 3

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Hypercalcemia Overview 6

Therapeutics Development 7

An Overview of Pipeline Products for Hypercalcemia 7

Hypercalcemia Therapeutics under Development by Companies 9

Hypercalcemia Therapeutics under Investigation by Universities/Institutes 10

Mid Clinical Stage Products 11

Comparative Analysis 11

Early Clinical Stage Products 12

Comparative Analysis 12

Hypercalcemia Therapeutics — Products under Development by Companies 13

Hypercalcemia Therapeutics — Products under Investigation by Universities/Institutes 14

Companies Involved in Hypercalcemia Therapeutics Development 15

Med Discovery SA 15

Hypercalcemia — Therapeutics Assessment 16

Assessment by Monotherapy Products 16

Assessment by Route of Administration 17

Assessment by Molecule Type 19

Drug Profiles 21

Parathyroid Hormone (1-34) - Drug Profile 21

Product Description 21

Mechanism of Action 21

R&D Progress 21

MDAB16 - Drug Profile 23

Product Description 23

Mechanism of Action 23

R&D Progress 23

Hypercalcemia Therapeutics - Dormant Products 24

Hypercalcemia — Product Development Milestones 25

Featured News & Press Releases 25

Dec 02, 2009: Genta to Support Initiation of New Clinical Trial using Ganite as Treatment for Life-Threatening Infections in Patients with Cystic Fibrosis 25

Jun 04, 2007: Phase 2 Clinical Results of Ganite® Plus Standard Therapy in Patients with Relapsed/Refractory Lymphoma Presented at ASCO 25

Mar 07, 2007: Genta and IDIS Announce Global Ex-U.S. Agreement for Named Patient/Compassionate Use Distribution of Ganite® and Genasense® 26

Mar 02, 2006: Randomized Trial Shows Ganite® Effective When Compared with A Leading Bisphosphonate in Patients with Cancer-Related Hypercalcemia 27

Dec 05, 2004: Ganite® Activity in Patients with Advanced Non-Hodgkin's Lymphoma Presented at Hematology Meeting 27

Mar 25, 2004: GenasenseTM and GaniteTM Featured in Presentations at the Annual Meeting of the American Association for Cancer Research 28

Sep 18, 2003: FDA Approves Genta's First Product, Ganite, for the Treatment of Cancer - Related Hypercalcemia 28

Apr 10, 2003: New Study Shows Biomarkers May Determine Responsiveness to Ganite in Non-Hodgkin's Lymphoma 29

Apr 01, 2003: Genta Completes FDA Submission of New Drug Application for Ganite; (gallium nitrate injection) 29

Jan 03, 2003: Genta Announces Reactivation of New Drug Application (NDA) for Ganite and Initiation of CMC Regulatory Filings Submissions Intended to Enable Product Launch during 2003 30

Appendix 31

Methodology 31

Coverage 31

Secondary Research 31

Primary Research 31

Expert Panel Validation 31

Contact Us 32

Disclaimer 32





List of Tables

Number of Products Under Development for Hypercalcemia, H1 2012 7

Products under Development for Hypercalcemia — Comparative Analysis, H1 2012 8

Number of Products under Development by Companies, H1 2012 9

Number of Products under Investigation by Universities/Institutes, H1 2012 10

Comparative Analysis by Mid Clinical Stage Development, H1 2012 11

Comparative Analysis by Early Clinical Stage Development, H1 2012 12

Products under Development by Companies, H1 2012 13

Products under Investigation by Universities/Institutes, H1 2012 14

Med Discovery SA, H1 2012 15

Assessment by Monotherapy Products, H1 2012 16

Assessment by Stage and Route of Administration, H1 2012 18

Assessment by Stage and Molecule Type, H1 2012 20

Hypercalcemia Therapeutics — Dormant Products 24





List of Figures

Number of Products under Development for Hypercalcemia, H1 2012 7

Products under Development for Hypercalcemia — Comparative Analysis, H1 2012 8

Products under Development by Companies, H1 2012 9

Products under Investigation by Universities/Institutes, H1 2012 10

Mid Clinical Stage Products, H1 2012 11

Early Clinical Stage Products, H1 2012 12

Assessment by Monotherapy Products, H1 2012 16

Assessment by Route of Administration, H1 2012 17

Assessment by Stage and Route of Administration, H1 2012 18

Assessment by Molecule Type, H1 2012 19

Assessment by Stage and Molecule Type, H1 2012 20

• Emergency Contraception in Tunisia
• Fabry Disease – Pipeline Review, H1 2013
• Gaucher's Disease – Pipeline Review, H1 2013
• Hereditary Angioedema (HAE) – Pipeline Review, H1 2013
• Hospital Acquired Pneumonia (HAP) – Pipeline Review, H1 2013
• Hyperphosphatemia In Chronic Kidney Disease – Pipeline Review, H1 2013
• Hyperuricemia – Pipeline Review, H1 2013
• Nephropathy – Pipeline Review, H1 2013
• Proteinuria – Pipeline Review, H1 2013
• Sports Nutrition in Argentina
• Sports Nutrition in Argentina
• Sports Nutrition in Canada
• Sports Nutrition in Denmark
• Sports Nutrition in Guatemala
• Sports Nutrition in Hong Kong, China
• Sports Nutrition in Norway
• Sports Nutrition in Tunisia
• Sports Nutrition in Turkey
• Viral Conjunctivitis – Pipeline Review, H1 2013
• Vitamins and Dietary Supplements in Argentina